<DOC>
	<DOC>NCT02770248</DOC>
	<brief_summary>The purpose of this study is to evaluate differences between treatments in mean change from baseline in 24-hr IOP at Week 4.</brief_summary>
	<brief_title>24-hr Intraocular Pressure Control With SIMBRINZA ®</brief_title>
	<detailed_description>Subjects will undergo washout of pre-study IOP-lowering medications for the appropriate duration, then undergo 2 eligibility visits. Eligible subjects will be randomized 1:1, to receive masked SIMBRINZA ® or Vehicle for 4 weeks. Two 24-hour visits will be conducted (Day 0 and Week 4) during which intraocular pressure will be collected every 2 hours. The expected duration of subject participation in the study is 10 weeks.</detailed_description>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Diagnosis of either openangle glaucoma or ocular hypertension; Able to attend all study related visits and be housed overnight at clinical site for the study assessments; Willing and able to sign an informed consent form; Other protocolspecified inclusion criteria may apply. Women of childbearing potential who are pregnant, intend to become pregnant during the study, breastfeeding, or not using adequate birth control; Diagnosed with any form of glaucoma other than open angle glaucoma or ocular hypertension; Ocular surgeries or procedures excluded by the protocol; Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol; Bestcorrected visual acuity score less than 55 ETDRS letters (equivalent to approximately 20/80 Snellen) in either eye; Other protocolspecific exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>